11
Shares of Biogen slid Friday after a European regulatory committee said the Alzheimer’s treatment Leqembi should not receive marketing approval.
Welcome to Gotcha News Daily, your premier destination for insightful commentary and analysis on a wide array of topics including politics, news, business, technology, and culture. Established in our digital form